Adia Nutrition Expands Rapidly, Tripling Sales Force with Regional Teams to Fuel U.S. and Worldwide Growth

Rhea-AI Summary

Adia Nutrition (OTCQB: ADIA) announced a major expansion of its sales operations by tripling its sales force and establishing four specialized teams. The restructuring creates dedicated teams for the East Coast, West Coast, Central U.S., and national/international markets to promote its Adialabs product line.

The company's portfolio includes AdiaVita (100M umbilical cord stem cells and 3T exosomes per dose), AdiaLink (3.5T exosomes per dose), and Glutaryl Transdermal Glutathione Spray. The expansion aims to enhance market reach and accessibility of these regenerative medicine products to healthcare facilities across the U.S. and globally.

Positive

• Tripling sales force size indicates significant business expansion
• Strategic division into four specialized regional teams for focused market penetration
• Growing international presence in key markets like Colombia and Mexico
• Product portfolio includes high-concentration stem cell and exosome formulations

Negative

• Sales team structure relies on independent contractors rather than direct employees
• Limited financial metrics provided to assess current market performance

News Market Reaction

-8.20%

1 alert

-8.20% News Effect

On the day this news was published, ADIA declined 8.20%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Winter Park, Florida--(Newsfile Corp. - September 9, 2025) - Adia Nutrition, Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine, is excited to announce a rapid expansion of its sales operations by tripling its sales force and creating four specialized teams to accelerate growth and market reach for its innovative Adialabs products. This strategic restructuring divides sales operations into dedicated teams for the East Coast, West Coast, Central U.S., and a team focused on national and international markets.

This expansion reinforces Adia Nutrition's commitment to making its Adialabs products, including AdiaVita (100 million umbilical cord stem cells and 3 trillion exosomes per dose), AdiaLink (3.5 trillion exosomes per dose), Glutaryl Transdermal Glutathione Spray, and all upcoming Adialabs products, more accessible to clinics, doctors, and healthcare facilities across the United States and globally. Each regional sales team will focus on building strong relationships with healthcare providers, using tailored strategies to promote Adialabs' portfolio of regenerative products.

"We are thrilled to triple our sales force and launch four dedicated sales teams to meet the surging demand for Adialabs' innovative products," said Larry Powalisz, CEO of Adia Nutrition, Inc. "By establishing specialized teams for the East Coast, West Coast, Central U.S., and national/international markets, we are positioning Adia Nutrition for rapid growth and delivering exceptional value to healthcare professionals. This structure empowers our sales representatives to forge deeper connections in their regions and drive adoption of AdiaVita, AdiaLink, Glutaryl Transdermal Glutathione Spray, and our exciting pipeline of upcoming products."

The regional sales teams will operate as independent contractors, focusing on high-demand areas for Adialabs products. Meanwhile, the existing national and international sales team will continue to expand Adia Nutrition's global footprint, particularly in markets like the U.S., Colombia, and Mexico, where interest in stem cell and exosome products is growing.

Adia Nutrition's Adialabs products are designed for use in clinical research and are manufactured in compliance with FDA regulations. The Glutaryl Transdermal Glutathione Spray, utilizing advanced sub-nanotechnology for enhanced absorption, is intended for athletes, wellness enthusiasts, and individuals seeking convenient antioxidant support. AdiaVita and AdiaLink are formulated to meet the highest standards for quality and compliance, supporting Adialabs' leadership in regenerative medicine research.

For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.

Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.

Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265160

FAQ

What is the significance of Adia Nutrition's (ADIA) sales force expansion in 2025?

Adia Nutrition has tripled its sales force and created four specialized teams covering East Coast, West Coast, Central U.S., and national/international markets to accelerate growth and market reach for its Adialabs products.

What are the main products in Adia Nutrition's (ADIA) portfolio?

Adia's main products include AdiaVita (100M stem cells and 3T exosomes), AdiaLink (3.5T exosomes), and Glutaryl Transdermal Glutathione Spray, all manufactured under FDA compliance.

How is Adia Nutrition (ADIA) structuring its new sales organization?

The company has created four specialized teams operating as independent contractors, focusing on East Coast, West Coast, Central U.S., and national/international markets.

What markets is Adia Nutrition (ADIA) targeting for international expansion?

Adia Nutrition is focusing on expanding its global footprint in markets with growing interest in stem cell and exosome products, particularly in the U.S., Colombia, and Mexico.

What is the concentration of stem cells in Adia Nutrition's AdiaVita product?

AdiaVita contains 100 million umbilical cord stem cells and 3 trillion exosomes per dose.